Share this article
Share this article
VANCOUVER, BC, Feb. 8, 2021 /PRNewswire/ - Chemistree Technology Inc. (CSE: CHM) (CSE: CHM.WT) (OTCQB: CHMJF) (the Company or Chemistree ) is pleased to inform shareholders that Chemistree investee ImmunoFlex™ has today announced that it is receiving advisory services and conditional research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). ImmunoFlex is now recruiting patients into a Phase 4 clinical trial designed to optimize the impact of FLEX 20
TM on the immune system. The funding from NRC IRAP will support a project focused on analyzing immune system data collected from this clinical trial, said ImmunoFlex CEO Chris Wagner. We are grateful for their support.
Chemistree Investee ImmunoFlex Receives Health Canada Approval For Flex 10 Product
News provided by
Share this article
Share this article
VANCOUVER, BC, Jan. 19, 2021 /PRNewswire/ - Chemistree Technology Inc. (CSE: CHM) (CSE: CHM.wt) (USOTCQB: CHMJF) (the Company or Chemistree ) is pleased to inform shareholders that Chemistree investee company ImmunoFlex™, a life sciences company developing clinically validated, pharmaceutical grade natural health products based on advancements in genomics research, today announced the approval of FLEX 10™ by Health Canada. At ImmunoFlex, we work with the immune system to strengthen, support, and enhance our body s natural surveillance and response system. said ImmunoFlex CEO Chris Wagner. FLEX 10 is the first product in our line up of products designed to achieve this goal so we could not be more delighted with the Health Canada approval.